MULTIPLE MYELOMA, REFRACTORY
Clinical trials for MULTIPLE MYELOMA, REFRACTORY explained in plain language.
Never miss a new study
Get alerted when new MULTIPLE MYELOMA, REFRACTORY trials appear
Sign up with your email to follow new studies for MULTIPLE MYELOMA, REFRACTORY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a booster shot make CAR-T last longer in myeloma?
Disease control Not yet recruitingThis study tests whether adding a drug called NT-I7 to standard CAR-T cell therapy can help the immune cells stay active longer in people with multiple myeloma that has come back or not responded to treatment. About 52 participants will receive either NT-I7 or a placebo after the…
Matched conditions: MULTIPLE MYELOMA, REFRACTORY
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 17, 2026 05:45 UTC
-
New Dual-Target CAR-T therapy takes on Hard-to-Treat myeloma
Disease control Not yet recruitingThis early-phase trial tests a new type of CAR-T cell therapy that targets two proteins (BCMA and GPRC5D) on myeloma cells. It is for adults aged 18-85 whose multiple myeloma has returned or stopped responding to standard treatments. The main goals are to check safety, find the r…
Matched conditions: MULTIPLE MYELOMA, REFRACTORY
Phase: EARLY_PHASE1 • Sponsor: Guangzhou Bio-gene Technology Co., Ltd • Aim: Disease control
Last updated May 17, 2026 05:30 UTC
-
Speedy CAR-T cells take on Hard-to-Treat myeloma in first human test
Disease control Not yet recruitingThis early-phase study tests a new CAR-T cell therapy called UF-KURE-BCMA for people with multiple myeloma that has come back or not responded to at least three prior treatments. The therapy uses a person's own immune cells, which are modified in a shorter process than standard C…
Matched conditions: MULTIPLE MYELOMA, REFRACTORY
Phase: PHASE1 • Sponsor: David Wald • Aim: Disease control
Last updated May 11, 2026 20:39 UTC
-
Turmeric powerhouse: could a curcumin infusion tame stubborn myeloma?
Disease control Not yet recruitingThis early-stage study tests a new form of curcumin (LipoCurc) given through a vein to people whose multiple myeloma has returned or stopped responding to treatment. The main goal is to find the highest safe dose by watching closely for side effects. About 20 adults will take par…
Matched conditions: MULTIPLE MYELOMA, REFRACTORY
Phase: PHASE1 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated May 06, 2026 16:14 UTC
-
Engineered immune cells take on Hard-to-Treat blood cancer
Disease control Not yet recruitingThis early-phase study tests a new treatment called SENL103 for people with multiple myeloma that has come back or stopped responding to standard therapies. The treatment uses a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. T…
Matched conditions: MULTIPLE MYELOMA, REFRACTORY
Phase: PHASE1, PHASE2 • Sponsor: Hebei Senlang Biotechnology Inc., Ltd. • Aim: Disease control
Last updated Apr 30, 2026 15:48 UTC